Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ – IT Business Net
Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para Correction – Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ €5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary S...
United States United Kingdom Mike Bolinder Cosmo Pharmaceuticals Drug Administration Company New Ordinary
Source: itbusinessnet.com